Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
about
Pharmacometabolomic signature of ataxia SCA1 mouse model and lithium effectsMetabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomicsMaternal Malnutrition in the Etiopathogenesis of Psychiatric Diseases: Role of Polyunsaturated Fatty AcidsPharmacometabolomics-aided Pharmacogenomics in Autoimmune DiseaseOmics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric DisordersSystems pharmacology: network analysis to identify multiscale mechanisms of drug actionMetabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolitesObesity and psychotic disorders: uncovering common mechanisms through metabolomicsRNA sequencing reveals a slow to fast muscle fiber type transition after olanzapine infusion in ratsFrom Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized MedicineLipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychoticsChronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin ResistanceMetabolomics enables precision medicine: "A White Paper, Community Perspective"Inflammation and the two-hit hypothesis of schizophrenia.Biomarkers for combat-related PTSD: focus on molecular networks from high-dimensional data.Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions.Bayesian semiparametric copula estimation with application to psychiatric geneticsOlanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactionsImpaired metabolic reactivity to oxidative stress in early psychosis patientsEvidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophreniaAtypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.Pharmacogenomics: a systems approach.Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors.A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.Non-targeted metabolite profiling reveals changes in oxidative stress, tryptophan and lipid metabolisms in fearful dogs.Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.Identifying individual differences of fluoxetine response in juvenile rhesus monkeys by metabolite profilingMetabolomic changes in autopsy-confirmed Alzheimer's diseaseMetabolome in schizophrenia and other psychotic disorders: a general population-based study.Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expressionPharmacometabolomics: implications for clinical pharmacology and systems pharmacology.Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease.A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Opioid use affects antioxidant activity and purine metabolism: preliminary results.Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain.
P2860
Q21559578-D3EA6109-61EB-4D07-9D73-1EB9ABC1B3FAQ21560953-FEB52BA1-5B06-476E-9F60-3D3B711C0630Q26740518-75E1B840-1626-4733-8A43-00B527752EE1Q26748481-7C8C882B-41A0-4EB8-B947-01B931899B2FQ26784904-D4B827DE-9D84-4FE1-B9B6-B58E8B891EB5Q26824166-C0F742DB-5DD6-4829-A15B-A19883A2920DQ26824720-E58AD84E-0D11-4ACB-8D81-FAD8EE1BE0FDQ27011617-CE180484-2519-4236-9D3B-6CCF5525D361Q27309270-FF6D8D58-2A22-451C-B82C-3DCC401A921EQ28067029-700C7CC0-65FD-4126-9A8C-E188278ADE13Q28534822-15CAECB5-A72B-490C-96B6-6ECBC18ECB63Q28555023-153B97B7-4840-4ED8-AB8F-A73E0AF165A2Q28831476-A845F93C-E686-4B6A-8DAA-498F571F3D00Q30422062-4BB2795A-5882-4BDF-8AE9-3A20E7B7B12AQ30849692-EE14A4CB-D194-4798-9729-5EA40D51F88BQ30885784-BE8E2ECF-55DF-48AB-A09E-CEDE6E77939AQ33867602-C6A235D8-DA25-4AFF-9765-161F9B17FA6EQ33942644-2C4BA732-C279-47B5-B6BB-E4118AA12271Q33989596-A963F22D-2911-408D-80CD-75678C2C988DQ34048645-8E2121E7-D6EB-433D-9A70-BFD733354C37Q34113374-8425A6DF-EFDD-40D4-9CA2-F5DD56B49119Q34117015-A17002A1-C6FA-4657-AA3C-671960CFAAF9Q34137575-FF10CC3D-0B7B-463A-B3C9-F6F475368B70Q34192207-C81DDAE4-C0BF-4288-A3F0-DE4B8672E53AQ34325802-F0C41F73-DCBA-4F1D-9086-E4302AE6A2C1Q34405264-5C1A52BA-4E98-411A-857A-BBEEEF7863E5Q34513600-E32241FE-0CFE-4F8A-A0A2-AAB1133FD915Q34555598-82E6D7FA-F679-4ACF-9968-1C3D2656A23EQ34613195-DC832F12-7E20-4FED-8ABE-F6E8241B5516Q34626655-F46247FC-5D57-4CFD-BDE5-8968DC85E9AEQ34657982-B1E266DA-D11A-48BC-8D41-EA4A95B55EF4Q34700264-80B57EE1-ED1E-4383-8127-009534546267Q34971495-0373597F-9029-46BB-97D7-A25CB79D9EBDQ35000399-C4D5649E-FEB4-42C2-BD27-B949987D9788Q35032056-E92C27B6-C322-4EAF-B6F1-BC62281CC780Q35115972-6A1C38B2-4B5F-49B7-9E93-A459CFAF2DD9Q35117457-58CB5FA2-3DDB-44D8-B761-904CEC477467Q35156543-CF3CC6F8-F40A-4F4A-A67B-36517B726D3FQ35247464-10ACD83A-ADAC-4576-81F3-DBDC3ACFFF80Q35284832-16F8EEB8-A1EF-48AF-8F50-6945E8A50D29
P2860
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@ast
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@en
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@nl
type
label
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@ast
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@en
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@nl
prefLabel
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@ast
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@en
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
@nl
P2093
P2860
P356
P1433
P1476
Metabolomic mapping of atypical antipsychotic effects in schizophrenia
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.MP.4002000
P407
P577
2007-04-17T00:00:00Z